Topic:
Emerging Markets
Latest Headlines
Latest Headlines
Report: Middle East, North Africa poised for major device and Dx growth
Forget Asia and China. Another booming region for medical devices in the coming years will be the Middle East and North Africa, with expectations that the market will double within 5 years from about $1 billion annually now, TradeArabia reports.
Medtronic rides emerging markets growth to strong quarter
Medtronic CEO Omar Ishrak has long said he want his company to get 20% of its revenue from emerging markets by 2016, and the device giant made some headway last quarter on the way to $4 billion in total revenue.
Hospira moves forward with two plants in India
FDA inspectors are slowly and deliberately reinspecting the Rocky Mount, NC, plant that has been at the heart of Hospira's manufacturing woes. That process will be lengthy, CEO F. Michael Ball predicts, and in the meantime, Hospira has a lot more that it is doing on its manufacturing network.
Africa is next on Big Pharma's emerging markets growth curve
What's Big Pharma's latest frontier? Africa. Yes, drugmakers have been active on the continent for years, primarily in fighting infectious diseases. But like other markets with an emerging middle class, Africa is seeing an increase in chronic disease--and that puts more Africans in line for prescription drugs.
Sproxil's running with Fast Company
An upstart tech company that has made foiling drug counterfeiters the heart of its business plan has caught the attention of the entrepreneurial class.
Kazakhstan government plans to build biologics plant
A number of drugmakers have targeted the central Asian country of Kazakhstan as a good arena in which to expand and now the government says it will get into the game as well.
ACRO: Proposed Indian trial reforms are unclear
India's Central Drugs Standard Control Organization has released its proposed clinical trial reforms, and while most fall in line with industry expectations, ACRO says the suggested rules on patient compensation are vague and problematic.
Pfizer's Singapore slash and burn could be good news for CROs
Pfizer is dumping its clinical research operation in Singapore, part of an effort to cut about $1.3 billion from its R&D budget, and the divestiture could mean more opportunity for outsourcers looking to partner with the drug giant.
Brazilian prize, Ache, said to be evaluating possible sale
With Western drugmakers sniffing around emerging markets in Latin America and elsewhere for the scent of a good deal, some companies there are weighing their futures, and their values, preparing themselves for the chase.
Pfizer cuts some more, closing R&D site in Singapore
As Pfizer continues to cut costs, it has just taken the ax to a clinical research facility in a market where others are beefing up, Singapore.
